RecruitingNot ApplicableNCT06066918

Prophylactic Pregabalin Treatment Following Spinal Cord Injury

The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain


Sponsor

Loewenstein Hospital

Enrollment

50 participants

Start Date

Jul 13, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Patients arriving to rehabilitation up to 3 months following SCI will be given (study group) or not (control group) Lyrica (75X2). They will be followed for central pain development.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Up to 3 months following traumatic or non-traumatic SCL
  • Ability to give informed consent and cooperate

Exclusion Criteria6

  • Pregnancy
  • Neurological or other medical conditions that may interfere with sensation
  • Neuropathic-like pain before recruitment (described as painful sensation of electric current, burning, numbness, tingling, pricking, or squeezing)
  • Being treated with Pregabalin
  • Blood creatinine levels >1.2 or creatinine clearance <60
  • Sensitivity to lactose

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPregabalin 75mg

Pregabalin 75 mg twice a day


Locations(1)

Loewenstein Rehabilitation Hospital

Raanana, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06066918


Related Trials